S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alnylam Launches Alnylam Assist™, Dedicated to Providing Support to Patients, Families, and Caregivers in Certain Genetic Diseases|
|New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists|
|Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)|
|Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia|
|Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia|
|Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias|
|Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at 10th Oligonucleotide Therapeutics Society (OTS) Meeting|
|Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis|
|Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development|
|Alnylam Presents New Pre-Clinical Data on RNAi Therapeutic Programs for Cardio-Metabolic Diseases at American Heart Association Scientific Sessions 2014|
Click above to view more mutual fund data and stats for alny - Alnylam Pharmaceuticals Inc.